Steven Cohen's TERN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 573,700 shares of Terns Pharmaceuticals, Inc. (TERN) worth $23.18 M, representing 0.03% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in TERN, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 2.22 M shares. Largest reduction occurred in Q4 2024, reducing 1.46 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Terns Pharmaceuticals (TERN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Terns Pharmaceuticals (TERN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +573,700 | New Buy | 573,700 | $40.40 |
| Q2 2025 | -160,725 | Sold Out | 0 | $0.00 |
| Q1 2025 | -1.09 M | Reduce 87.16% | 160,725 | $2.76 |
| Q4 2024 | -1.46 M | Reduce 53.76% | 1.25 M | $5.54 |
| Q3 2024 | +17,139 | Add 0.64% | 2.71 M | $8.34 |
| Q2 2024 | +469,176 | Add 21.12% | 2.69 M | $6.81 |
| Q1 2024 | +2.22 M | New Buy | 2.22 M | $6.56 |
| Q4 2023 | -571,265 | Sold Out | 0 | $0.00 |
| Q3 2023 | +571,265 | New Buy | 571,265 | $5.03 |
| Q2 2023 | -629,098 | Sold Out | 0 | $0.00 |
| Q1 2023 | +395,598 | Add 169.42% | 629,098 | $11.84 |
| Q4 2022 | +233,500 | New Buy | 233,500 | $10.18 |
| Q3 2022 | -500,000 | Sold Out | 0 | $0.00 |
| Q2 2022 | +377,427 | Add 307.92% | 500,000 | $2.48 |
| Q1 2022 | +122,573 | New Buy | 122,573 | $2.97 |
Steven Cohen's Terns Pharmaceuticals Investment FAQs
Steven Cohen first purchased Terns Pharmaceuticals, Inc. (TERN) in Q1 2022, acquiring 122,573 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Terns Pharmaceuticals, Inc. (TERN) for 15 quarters since Q1 2022.
Steven Cohen's largest addition to Terns Pharmaceuticals, Inc. (TERN) was in Q1 2024, adding 2,221,200 shares worth $14.57 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 573,700 shares of Terns Pharmaceuticals, Inc. (TERN), valued at approximately $23.18 M.
As of the Q4 2025 filing, Terns Pharmaceuticals, Inc. (TERN) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Terns Pharmaceuticals, Inc. (TERN) was 2,707,515 shares, as reported at the end of Q3 2024.